Similarly, treatment with a bromodomain and extra-terminal motif (BET) protein inhibitor (BETi) suppresses EVI1 expression and reduces the viability of EVI1 overexpressing AML cells [60]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.